GlassScriptPhysician profile
Brian Ray Muir
NPI 1386872810
$1,918.48
in general payments reported to CMS, 2019-2025
25 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $136 · 2021: $44.28 · 2022: $102 · 2023: $324 · 2024: $557 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $151.37 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Comsort, INC | $150.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $143.18 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.32 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $103.45 | 2019-2022 | |
| Astellas Pharma US INC | $88.77 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $83.29 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $80.80 | 2022-2023 | |
| Amgen INC. | $76.71 | 2019-2020 | |
| Lilly USA, LLC | $62.81 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $56.33 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $38.09 | 2019-2024 | Rotateq, Gardasil 9, Vaxelis |
| Inspire Medical Systems, INC. | $33.35 | 2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.84 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $24.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $22.79 | 2019-2020 | |
| Radius Health, INC. | $16.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2025 | Eliquis |
| Allergan, INC. | $13.07 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.01 | 2020 | |
| Corium, LLC | $12.79 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Muir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.